072020 — Choong Ang Vaccine Laboratory Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩103bn
- KR₩84bn
- KR₩42bn
- 82
- 55
- 59
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 24,325 | 22,767 | 21,468 | 17,987 | 27,424 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,404 | 3,410 | 3,442 | 3,401 | 4,502 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 42,350 | 42,342 | 39,844 | 39,590 | 50,561 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 47,344 | 57,891 | 66,091 | 66,969 | 63,272 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 96,567 | 104,979 | 112,952 | 114,859 | 119,593 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7,359 | 12,454 | 14,361 | 13,313 | 12,653 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 10,200 | 17,429 | 19,976 | 19,554 | 19,788 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 86,367 | 87,550 | 92,976 | 95,304 | 99,804 |
Total Liabilities & Shareholders' Equity | 96,567 | 104,979 | 112,952 | 114,859 | 119,593 |
Total Common Shares Outstanding |